文献リスト

1）Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl): S43-54

2）Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2013 Mar 1. [Epub ahead of print]

3）Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53: 733-40

4）Oechslin E, Mebus S, Schulze-Neick I, et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. Curr Cardiol Rev. 2010; 6: 363-72

5）Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-537

6）循環器病の診断と診療に関するガイドライン（2010年度合同研究班報告）．成人先天性心疾患診療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011_niwa_d.pdf

7）循環器病の診断と診療に関するガイドライン（2011年度合同研究班報告）．肺高血圧症治療ガイドライン（2012年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_d.pdf

8）Barst RJ, McGoon MD, Elliott CG, et, al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012; 125: 113-22

9）Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009; 95: 312-7

10）Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112: 828-35

11）Perloff JK. Myocardial growth and the development and regression of increased ventricular mass. In: Perloff JK, Child JS, Aboulhosn J, editors 3rd ed. Congenital Heart Disease in Adults. Philadelphia: Saunders Elsevier; 2009. p. 60-473

12）Mebus S, Schulze-Neick I, Oechslin E, et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment-Study Results. Curr Cardiol Rev. 2010; 6: 356-62

13）Kaemmerer H, Mebus S, Schulze-Neick I, et al. The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options. Curr Cardiol Rev. 2010; 6: 343-55

14）Broberg CS, Jayaweera AR, Diller GP, et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol. 2011; 107: 595-9

15）Van De Bruaene A, Delcroix M, Pasquet A, et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J. 2011; 32: 2790-9

16）Wijesekera VA, Radford DJ. Hypertrophic osteoarthropathy in Eisenmenger syndrome. Congenit Heart Dis. 2013; 8: E65-9

17）Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012; 7: 268-76

18）Mulder BJ. Changing demographics of pulmonary arterial hypertension in congenital heart disease. Eur Respir Rev. 2010; 19: 308-13

19）Inohara T, Niwa K, Yao A, et al. Survey of the current status and management of Eisenmenger syndrome: A Japanese nationwide survey. J Cardiol. 2013 Oct 18. pii: S0914-5087(13)00268-2

20）van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011; 124: 1755-64

21）Prapa M, McCarthy KP, Dimopoulos K, et al. Histopathology of the great vessels in patients with pulmonary arterial hypertension in association with congenital heart disease: Large pulmonary arteries matter too. Int J Cardiol. 2013; 168: 2248-54

22）Meng J, Qian Y, Xiao X. Eisenmenger syndrome complicated by pulmonary artery dissection. Thorac Cardiovasc Surg. 2012; 60 Suppl 2: e1-2

23）Subbaiah M, Kumar S, Roy KK, et al. Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India. Arch Gynecol Obstet. 2013; 288: 305-9

24）Katsuragi S, Yamanaka K, Neki R, et al. Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. Circ J. 2012; 76: 2249-54

25）Wang H, Zhang W, Liu T. Experience of managing pregnant women with Eisenmengerʼs syndrome: maternal and fetal outcome in 13 cases. J Obstet Gynaecol Res. 2011; 37: 64-70

26）Curry RA, Fletcher C, Gelson E, et al. Pulmonary hypertension and pregnancy--a review of 12 pregnancies in nine women. BJOG. 2012; 119: 752-61

27）Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003; 91: 632-5

28）Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114: 48-54

29）Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008; 127: 27-32

30）Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120: 301-5

31）Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006; 114: 1807-10

32）Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013; 164: 64-9

33）Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). Eur Heart J. 2010; 23: 2915-57

34）Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010; 9: 1124-31

35）Sakazaki H, Niwa K, Nakazawa M, et al. Clinical features of adult patients with Eisenmengerʼs syndrome in Japan and Korea. Int J Cardiol. 2013; 167: 205-9

36）Kaemmerer H, Gorenflo M, Hoeper M, et al. Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation. Dtsch Med Wochenschr. 2013; 138: 1247-52

37）Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013; 167: 2239-43

38）DʼAlto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart. 2010; 96: 1475-9

39）Williams R, Houser L, Miner P, et al. Efficacy and safety of bosentan in adults with simple and complex Eisenmengerʼs syndrome. Congenit Heart Dis. 2012; 7: 12-5

40）Gatzoulis MA, Beghetti M, Galie N, et al. Longer term Bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008; 127: 27-32

41）Monfredi O, Griffiths L, Clarke B, et al. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol. 2011; 108: 1483-8

42）Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117: 3010-9

43）Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011; 107: 1381-5

44）Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011; 97: 1876-81

45）Garg N, Sharma MK, Sinha N. Role of sildenafil in severe pulmonary arterial hypertension: clinicalefficacy and dose response relationship. Int J Cardiol. 2007; 120: 306-13

46）Kaemmerer H, Niwa K, Qechslin E, et al. Pul-monary arterial hypertension in congenital heart disease: Eisenmengerʼs syndrome- A global prospective. Bremen, London, Boston: Uni-Med Velag AG; 2013. p. 37-47

47）Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011; 6: 424-31

48）Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999; 99: 1858-65

49）Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002; 39: 1496-502

50）Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41: 2119-25

51）Tamura Y, Ono T, Fukuda K, et al. Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). Adv Ther. 2013; 30: 459-71

52）Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26: 858-63

53）Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(Suppl): S78-84

54）DʼAlto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012; 155: 378-82

55）Grutter G, Guccione P, Mantione L, et al. A multiple combined treatment in an adult patient with Eisenmengerʼs syndrome. Int J Cardiol. 2011; 151: 372-3

56）Van De Bruaene A, De Meester P, Voigt JU, et al. Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. Int J Cardiol. 2013; 168: 1386-92

57）Schuuring MJ, van Riel AC, Vis JC, et al. High-sensitivity Troponin T Is Associated with Poor Outcome in Adults with Pulmonary Arterial Hypertension due to Congenital Heart Disease. Congenit Heart Dis. 2013; 8: 520-6

58）Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in eisenmenger syndrome. Circulation. 2012; 126: 1461-8

59）Reardon LC, Williams RJ, Houser LS, et al. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome. Am J Cardiol. 2012; 110: 1523-6

60）Diller GP, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart. 2012; 98: 736-42

61）Van De Bruaene A, De Meester P, Voigt JU, et al. Right ventricular function in patients with Eisenmenger syndrome. Am J Cardiol. 2012; 109: 1206-11

62）Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012; 126: 1944-54

63）Rosenzweig EB, Barst RJ. Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery. Prog Cardiovasc Dis. 2012; 55: 128-33

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp